Brief: Nippon Shinyaku Co Says Johnson & Johnson Obtains Approval Of Opsumit
22/12/2025 07:37
Dec 22 (Reuters) - Nippon Shinyaku Co Ltd 4516.T: NIPPON SHINYAKU CO: JOHNSON & JOHNSON OBTAINS APPROVAL OF OPSUMIT FOR TREATMENT OF PEDIATRIC PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION IN JAPAN Source text: [ID:] Further company coverage: 4516.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nippon Shinyaku
See all newsTable: Nippon Shinyaku -Q1 group results (IFRS)
Brief: Elixirgen Therapeutics And Nippon Shinyaku Enter Into An Option Agreement For The Development And Commercialization Of Exg-7001 For Duchenne Muscular Dystrophy
Table: Nippon Shinyaku -2025/26 group results (IFRS)
Table: Nippon Shinyaku -2025/26 parent results
Table: Nippon Shinyaku -9-MTH group results (IFRS)